Clinical Study of BCG Vaccine for Intradermal Injection

Tuberculosis Clinical Trial

Official title:

Randomized, Blinded, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of BCG Vaccine for Intradermal Injection in 6-65 Year Olds

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04563273
• Other study ID #: BCG-I-healthy
• Status: Completed
• Phase: Phase 1
• Start date: October 21, 2020
• Est. completion date: October 30, 2022

Study information

• Verified date: May 2023
• Source: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study used a randomized, dose-escalation, blinded, placebo-controlled trial design. In this trial, 160 subjects were enrolled. The test vaccines are divided into four dose groups: dose group 1 (0.025mg / 0.1ml / person), dose group 2 (0.05mg / 0.1ml / person), dose group 3 (0.075mg / 0.1ml / person), dose group 4 (0.1mg / 0.1ml / person), each Each dose group was enrolled according to 18-45、 46-65 、6-10、11-17years old . The 4 doses are in descending order in the order of 18-45, 46-65, 11-17, and 6-10 years old. Each age group in the same dose group was enrolled in 8 experimental BCG subjects and 2 placebo subjects. Among subjects aged 6-65 years, the dose group 2 study will be carried out after the safety assessment 14 days after the dose group 1 vaccination, and the dose group 3 study will be carried out after completing the safety assessment 14 days after the dose group 2 vaccination. Dose group 3 studies were carried out after safety assessment 14 days after vaccination. Within the same dose group, after completing the safety assessment 14 days after vaccination for the previous age group, vaccination for the next age group is carried out.

Description:

The study used a randomized, dose-escalation, blinded, placebo-controlled trial design. In this trial, 160 subjects were enrolled. The test vaccines are divided into four dose groups: dose group 1 (0.025mg / 0.1ml / person), dose group 2 (0.05mg / 0.1ml / person), dose group 3 (0.075mg / 0.1ml / person), dose group 4 (0.1mg / 0.1ml / person), each Each dose group was enrolled according to 18-45、 46-65 、6-10、11-17years old . The 4 doses are in descending order in the order of 18-45, 46-65, 11-17, and 6-10 years old. Each age group in the same dose group was enrolled in 8 experimental BCG subjects and 2 placebo subjects. Among subjects aged 6-65 years, the dose group 2 study will be carried out after the safety assessment 14 days after the dose group 1 vaccination, and the dose group 3 study will be carried out after completing the safety assessment 14 days after the dose group 2 vaccination. Dose group 3 studies were carried out after safety assessment 14 days after vaccination. Within the same dose group, after completing the safety assessment 14 days after vaccination for the previous age group, vaccination for the next age group is carried out. BCG-PPD and EC skin test were performed during the screening period, and the skin test results were followed up at 48 hours; blood routine, urine routine, blood biochemistry, HIV antibody test, electrocardiogram, chest X-ray examination, physical examination, vital signs (heart rate, blood pressure) And body temperature), female subjects of childbearing age undergo a blood pregnancy test. Those eligible for entry will receive a dose of the trial vaccine or placebo on the same day (day 0); Observe vital signs (heart rate, blood pressure and body temperature), reactions at the inoculation site, and reactions at the non-inoculation site at 30 minutes, 7 days, and 14 days after vaccination; Blood routine, urine routine, blood biochemistry, electrocardiogram examination on the 14th day after vaccination; BCG-PPD and EC skin tests were performed on the 84th and 180th days after inoculation. If the blood routine, urine routine, blood biochemistry, electrocardiogram examinations after vaccination are abnormal and have clinically meaningful results, a re-test is required. Under special circumstances, the number of re-tests can be appropriately increased until the follow-up outcome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: October 30, 2022
• Est. primary completion date: October 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Aged 6-65 years old, able to provide legal identification;

2. The guardian and/or I agree to participate in this trial, and have the ability to understand the research procedures and sign an informed consent form, and are willing and able to comply with the requirements of the research protocol;

3. The female agrees to have no birth plan within 180 days after participating in the research and voluntarily take effective contraceptive measures;

4. There is no contraindication to BCG vaccination (?Known allergy to any component of this vaccine; ?Patients suffering from acute disease, severe chronic disease, acute episode of chronic disease and fever; ?Immune deficiency, immunocompromised or receiving immunosuppression Treatment; ?patients with encephalopathy, uncontrolled epilepsy and other progressive neurological diseases; ?pregnant women; ?patients with eczema or other skin diseases), no history of tuberculosis;

5. There are no contraindications to the use of BCG-PPD and EC (patients suffering from acute infectious diseases (such as measles, pertussis, influenza, pneumonia, etc.), acute conjunctivitis, acute otitis media, patients with extensive skin diseases and allergic constitution);

6. According to the medical history, physical examination and laboratory index test results, the investigator judges to be healthy (for example: no history of tumor, abnormal laboratory index but no clinical significance);

7. The average diameter of BCG-PPD 48-hour skin test induration is less than 5mm without double circles, blisters, necrosis and lymphangitis. The average diameter of EC 48-hour skin test induration and redness is less than 5mm without blisters, necrosis, and lymphangitis. reaction.

Exclusion Criteria:

1. Any previous history of severe side effects of vaccines or drugs, such as urticaria, dyspnea, angioedema;

2. The interval between inoculation of live attenuated vaccine is less than 28 days, and the interval of other vaccines is less than 14 days;

3. Those who have a history of convulsions, epilepsy, mental illness and/or family history of mental illness;

4. Human immunodeficiency virus (HIV) antibody test results are positive;

5. Have received blood or blood-related products within 3 months before screening;

6. A history of drug abuse upon inquiry;

7. Women who are breastfeeding;

8. Those who have participated in other clinical trials in the past 3 months and used study drugs;

9. 6-17 years old systolic blood pressure =120mmHg and/or diastolic blood pressure =80 mmHg; 18-65 years old diastolic blood pressure =90mmHg and/or systolic blood pressure =140mmHg;

10. Those with axillary body temperature =37.3?;

11. Disabled upper limbs;

12. The researcher believes that the subject has any conditions that may affect the evaluation of the research purpose.

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Biological:
• BCG vaccine 1(0.025mg/0.1ml/person)
Intradermal injection of 0.025mg/0.1ml/person dose BCG.
• BCG vaccine 2 (0.05mg/0.1ml/person)
Intradermal injection of 0.05mg/0.1ml/person dose BCG.
• BCG vaccine 3(0.075mg/0.1ml/person)
Intradermal injection of 0.075mg/0.1ml/person dose BCG.
• BCG vaccine 4 (0.075mg/0.1ml/person)
Intradermal injection of 0.075mg/0.1ml/person dose BCG.
• Placebo of BCG vaccine (0.1ml/person)
Intradermal injection of 0.1ml/person dose Placebo.

Locations

Country	Name	City	State
China	Sichuan Center for Disease Control and Prevention	Chendu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Country where clinical trial is conducted

China, 

References & Publications (2)

Expanded programme on immunization. Immunization schedules in the WHO European Region, 1995. Wkly Epidemiol Rec. 1995 Aug 4;70(31):221. No abstract available. English, French. — View Citation

Tuberculosis Prevention Trial. Trial of BCG vaccines in south India for tuberculosis prevention. 1979. Indian J Med Res. 2013 Mar;137(3):15 p following p571. No abstract available. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events after vaccination	Evaluate safety indicators before vaccination, 30 minutes, 7 days, and 14 days after vaccination. Collect all AEs 30 minutes after vaccination, 0-14 days of collected adverse events, 0-30 days of non-collected adverse events, within 6 months SAE, to evaluate the safety and tolerability of BCG vaccine for intradermal injection used in the test in people aged 6 to 65 years old with negative BCG-PPD and EC skin test	Up to 6 months after the sixth time injection
Secondary	Positive conversion rate of BCG-PPD skin test 12 weeks and 6 months after vaccination	BCG-PPD skin tests were conducted 12 weeks and 6 months after inoculation of the corresponding test drugs and placebo to evaluate the positive conversion rate of BCG-PPD after BCG vaccination for intradermal injection	Up to 6 months after the sixth time injection
Secondary	Positive conversion rate of EC skin test 12 weeks and 6 months after vaccination	EC skin tests were conducted 12 weeks and 6 months after inoculation of the corresponding test drugs and placebo to evaluate the positive conversion rate of EC after BCG vaccination for intradermal injection	Up to 6 months after the sixth time injection